A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)
2026-09-14
عنوان الدراسة
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)
داعم الدراسة
GSK Research & Development Limited
دواء الدراسة
Efimosfermin alfa
رقم بروتوكول الدراسة
306246
حالة الدراسة
Ongoing
موقع الدراسة
1.King Fahad Specialist Hospital - Dammam 2.King Faisal Specialist Hospital and Researech Center - Riyadh 3.King Abdulaziz Medical City - Jeddah 4.Imam Abdulrahman Bin Faisal University - Dammam
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.